The CAPItello-291 Trial: A New Horizon in Breast Cancer Treatment The CAPItello-291 Trial, a Phase III double-blind randomized trial conducted in 2023, has significantly contributed to the evolving landscape of breast cancer treatment, particularly for hormone receptor-positive advanced cases. Objective … Read More
Oncology
RUBY Trial Summary: Dostarlimab for Endometrial Cancer
The RUBY Trial: A New Chapter in Endometrial Cancer Treatment Recent results from the RUBY Trial have introduced a significant advancement in the treatment of primary advanced or recurrent endometrial cancer. The phase 3, randomized, double-blind trial meticulously evaluated the … Read More
COSMIC-313 Trial: Cabozantinib in Renal Cell Cancer
The COSMIC-313 Trial: A New Frontier in Renal-Cell Carcinoma Treatment In the landscape of oncology, renal-cell carcinoma stands as a formidable challenge, often presenting at advanced stages and with a dire need for effective treatments. Enter the COSMIC-313 Trial, a … Read More
NSCLC Treatment: The AEGEAN Trial Breakthrough
“Innovations in NSCLC Treatment: The AEGEAN Trial Breakthrough” In recent years, the pursuit of more effective treatments for non-small-cell lung cancer (NSCLC) has been relentless. The AEGEAN trial of 2023, as reported in the esteemed New England Journal of Medicine … Read More
VISION Trial: Lutetium-177–PSMA-617 for Metastatic Prostate Cancer
The VISION trial was a phase 3 international, open-label study that aimed to evaluate the efficacy of Lutetium-177 (177Lu)–PSMA-617, a radioligand therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). This type of cancer remains fatal despite recent advancements, and … Read More
KEYNOTE 671 Trial: Perioperative Pembrolizumab in Early-Stage NSCLC
KEYNOTE 671 Trial Summary Introduction:The KEYNOTE 671 trial aimed to investigate the efficacy of perioperative pembrolizumab, an immune checkpoint inhibitor, in patients with resectable early-stage non–small-cell lung cancer (NSCLC). This randomized, double-blind, phase 3 trial assessed the benefits of neoadjuvant … Read More
ZUMA 7 Trial: Axi-Cel Therapy- A New Hope for Patients with Early Relapsed or Refractory Large B-Cell Lymphoma
ZUMA 7 Trial Summary Patients with early relapsed or refractory large B-cell lymphoma often face poor prognoses after receiving first-line chemoimmunotherapy. However, a recent international, phase 3 trial has demonstrated promising results with the use of axicabtagene ciloleucel (axi-cel), an … Read More
SUNLIGHT Trial: Prolonging Survival for Advanced Colorectal Cancer Patients with Trifluridine–Tipiracil and Bevacizumab
The groundbreaking “SUNLIGHTTrial” recently highlighted the potential of the combined treatment of Trifluridine–Tipiracil (FTD–TPI) and Bevacizumab in extending the lifespan of patients with advanced colorectal cancer. The promising phase 3 study builds on prior research suggesting the efficacy of FTD–TPI … Read More
CATCH Trial Summary: Tinzaparin for VTE in Cancer
2015 CATCH TRIAL Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer phase 3, multinational, open-label, randomized controlled trial Objective: To assess the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic … Read More
ALLIANCE Trial Summary: Axillary Dissection in Breast Cancer
2020 ALLIANCE TRIAL Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis Multicenter, phase 3, randomized controlled trial M Objective: To determine whether the 10-year overall survival … Read More